News & Events

• September 8, 2022
  

  C-Path’s Kristen Swingle Named President

  Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
• June 2, 2022
  

  xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records

  xCures today announced has joined the Critical Path Institute’s (C-Path) Cure Drug Repurposing Collaboratory (CDRC). CRDC is operated by C-Path as a public-private partnership with the U.S. Food and Drug Administration (FDA), and the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).

• April 7, 2022
  

  Doctor With Rare Disease And No Answers Decides To Find His Own Cure

  David Fajgenbaum was diagnosed with Castleman disease as a medical student. In Chasing My Cure, he recounts crowd-sourcing his own treatment with a global network of doctors, scientists and patients.

• April 7, 2022
  

  Castleman’s Disease: Behind the Mystery of Rare Disease

  We’re going Behind the Mystery of two rare diseases: Castleman disease and chondrosarcoma.

  There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades. Inhibrx, a clinical-stage biotechnology company, is dedicated to helping people with life-threatening conditions. They are developing a therapeutic option for chondrosarcoma called INBRX-109, which is currently in clinical trials.

• November 9, 2021
  

  C-Path Joins New Coalition to Improve Patient Care and Address Unmet Medical Needs through Community-Level Clinical Trials

  WASHINGTON and TUCSON, Ariz., November 9, 2021 — Launching today, the Advancing Clinical Trials at the Point of Care (ACT@POC) Coalition will generate quality clinical research evidence in real time to better evaluate treatments and therapeutics, including those to treat COVID-19. The Coalition will engage a broader, more diverse group of patients and providers and develop digital health tools that make clinical trials simpler to run and more accessible to patients.